Mei Ri Jing Ji Xin Wen·2025-08-22 09:52Core Insights - Rongchang Bio reported a revenue of approximately 1.098 billion yuan for the first half of 2025, representing a year-on-year increase of 48.02% [2] - The net loss attributable to shareholders was approximately 450 million yuan, with a basic earnings per share loss of 0.83 yuan [2] - In comparison, the revenue for the same period in 2024 was about 742 million yuan, with a net loss of approximately 780 million yuan and a basic earnings per share loss of 1.45 yuan [2] Financial Performance - Revenue for H1 2025: 1.098 billion yuan, up 48.02% year-on-year [2] - Net loss for H1 2025: 450 million yuan [2] - Basic earnings per share for H1 2025: loss of 0.83 yuan [2] - Revenue for H1 2024: 742 million yuan [2] - Net loss for H1 2024: 780 million yuan [2] - Basic earnings per share for H1 2024: loss of 1.45 yuan [2]